[Chronic bacterial prostatitis with microbiological diagnosis: a report of two cases]. [PDF]
García-Bujalance S+4 more
europepmc +3 more sources
Could Urology’s Antimicrobial Stewardship Be Enhanced by the Routine Use of the Meares and Stamey Test? [PDF]
Background/Objectives: Chronic bacterial prostatitis (CBP) is a prevalent urological condition significantly impacting patients’ quality of life. Accurate diagnosis is essential to differentiate bacterial from non-bacterial prostatitis and to guide ...
Simone Botti+7 more
doaj +2 more sources
Oral fosfomycin for the treatment of chronic bacterial prostatitis. [PDF]
Karaiskos I+7 more
europepmc +2 more sources
Case Report: Chronic Bacterial Prostatitis Treated With Phage Therapy After Multiple Failed Antibiotic Treatments. [PDF]
Johri AV+5 more
europepmc +3 more sources
Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis. [PDF]
Los-Arcos I+6 more
europepmc +3 more sources
Assessment of Sexual Function in Relation to Microbiological Findings in Patients with Chronic Bacterial Prostatitis. [PDF]
Magri V+3 more
europepmc +2 more sources
Probiotics in the Management of Chronic Bacterial Prostatitis Patients: A Randomized, Double-Blind Trial to Evaluate a Possible Link Between Gut Microbiota Restoring and Symptom Relief. [PDF]
Vocca C+15 more
europepmc +2 more sources
Objectives. The purpose of the scientific paper was to analyze data and evidence from existing sources for infravesical obstruction caused by the complications of nonbacterial chronic prostatitis. Materials and methods.
Artur Colța
doaj +3 more sources
Chlamydia trachomatis versus common uropathogens as a cause of chronic bacterial prostatitis: Is there any difference? Results of a prospective parallel-cohort study. [PDF]
Cai T+8 more
europepmc +2 more sources
Chronic bacterial prostatitis reduces the reproductive function of men and worsens the quality of life. Impairment of the immune system in chronic bacterial prostatitis requires immunocorrection and use of additional immunomodulatory therapy.
Kh. S. Ibishev+8 more
doaj +1 more source